20391 ⎘
Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom; Quinolines; Isoquinolines 2-Quinolinones, e.g. carbostyril
COMBINATION FORMULATION OF LAQUINIMOD AND GLATIRAMER ACETATE WITH AMINO ACIDS
#302Treatment of Glaucoma Using Laquinimod
#303Compositions and methods of inhibiting histone deacetylases
#304Pharmaceutical Composition
#305Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear disorders
#306TREATMENT OF CROHN'S DISEASE WITH LAQUINIMOD
#307INDUCING BROWN FAT FATE AND FUNCTION
#308TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FLUPIRTINE
#309Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients
#310Substituted heterocyclic acetamides as kappa opioid receptor (KOR) agonists
#311Treatment of Multiple Sclerosis With Combination of Laquinimod and Glatiramer Acetate
#312Respirable agglomerates of porous carrier particles and micronized drug
#313Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use
#314TREATMENT OF CROHN'S DISEASE USING LOW DOSES OF LAQUINIMOD
#315Crystalline microparticles of a beta-agonist coated with a fatty acid
#316TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND TERIFLUNOMIDE
#317LAQUINIMOD FOR TREATMENT OF CANNABINOID RECEPTOR TYPE 1(CB1) MEDIATED DISORDERS
#318Inhalable medicaments
#319NOVEL DOSAGE FORM AND FORMULATION OF ABEDITEROL
#320Inhibitors of HSV nucleotidyl transferases and uses therefor
#321TREATMENT OF MULTIPLE SCLEROSIS BY ALEMTUZUMAB INDUCTION FOLLOWED BY LAQUINIMOD THERAPY
#322TREATMENT OF CROHN'S DISEASE WITH LAQUINIMOD
#323LAQUINIMOD FOR REDUCING THALAMIC DAMAGE IN MULTIPLE SCLEROSIS
#3245-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF
#325Laquinimod Combination Therapy For Treatment Of Multiple Sclerosis
#326NOVEL COMPOUND WITH ANTIBACTERIAL ACTIVITY
#327Methods for treating spinocerebellar ataxia type I using RPA1
#328Treatment of BDNF-Related Disorders Using Laquinimod
#329TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FAMPRIDINE
#330Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity
#331TREATMENT OF LUPUS ARTHRITIS USING LAQUINIMOD
#332DRY POWDER INHALERS COMPRISING A CARRIER OTHER THAN LACTOSE AND A TERNARY COMPONENT
#333GENE EXPRESSION BIOMARKERS OF LAQUINIMOD RESPONSIVENESS
#334Small molecules to enhance P53 activity
#335Anthelmintic compounds and compositions and method of using thereof
#336TREATMENT OF MULTIPLE SCLEROSIS BY ALEMTUZUMAB INDUCTION FOLLOWED BY LAQUINIMOD THERAPY
#337Treatment of Multiple Sclerosis With Combination of Laquinimod and Interferon-Beta
#338TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FLUPIRTINE
#339N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-QUINOLINECARBOXAMIDE, PREPARATION AND USES THEREOF
#340N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-QUINOLINECARBOXAMIDE, PREPARATION AND USES THEREOF
#341Method of screening for a compound for inhibitory activity of FN14-tweak interaction
#342Use of glycopyrrolate for treating tachycardia
#343Heterocyclic GSK-3 allosteric modulators
#344Aqueous ophthalmic suspension of crystalline rebamipide
#345Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists
#346Compounds for inhibiting drug-resistant strains of HIV-1 integrase
#347Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
#348TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD
#349PHARMACEUTICAL COMPOSITIONS
#350Oral pharmaceutical composition for preventing or treating dry eye syndrome comprising rebamipide or a prodrug thereof
#351Treatment Of Neurodegenerative Diseases With Combination Of Laquinimod And Fingolimod
#352Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
#353TRANSDERMAL FORMULATIONS OF LAQUINIMOD
#354Method of treatment of Hypoxia Inducible Factor (HIF)-related conditions
#355USE OF HIGH DOSE LAQUINIMOD FOR TREATING MULTIPLE SCLEROSIS
#356TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND DIMETHYL FUMARATE
#357DEAMORPHIZATION OF SPRAY-DRIED FORMULATIONS VIA SPRAY-BLENDING
#358USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNF THERAPY
#359Methods and compositions for treatment of demyelinating diseases
#360Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity
#361Combination of (3S,3S′) 4,4′-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent
#362Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear disorders
#363LAQUINIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) PATIENTS WITH A HIGH DISABILITY STATUS
#364Quinolone derivatives
#365USE OF HIGH DOSE LAQUINIMOD FOR TREATING MULTIPLE SCLEROSIS
#366METHODS OF USING FEXARAMINE AND AGENTS THAT INCREASE SYMPATHETIC NERVOUS SYSTEM ACTIVITY TO PROMOTE BROWNING OF WHITE ADIPOSE TISSUE
#367PHARMACEUTICAL COMPOSITION COMPRISING REBAMIPIDE
#368Quinolinone derivatives
#369INHALATION COMPOSITIONS
#370Quinolone compound and pharmaceutical composition
#371DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR
#372COMBINATION OF LAQUINIMOD AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE
#373DRY POWDER INHALERS COMPRISING A CARRIER OTHER THAN LACTOSE AND A TERNARY COMPONENT
#374DRY POWDER INHALERS COMPRISING A CARRIER OTHER THAN LACTOSE
#375Inhibitors of CRL4 ubiquitin ligase and uses thereof
#376Autoimmune disorder treatment using RXR agonists
#3775-HT1A receptor subtype agonist
#378USE OF LAQUINIMOD TO DELAY HUNTINGTON'S DISEASE PROGRESSION
#379COMPOSITIONS COMPRISING MUSCARINIC RECEPTOR ANTAGONIST AND GLUCOSE ANHYDROUS
#380COMPOSITIONS COMPRISING MUSCARINIC RECEPTOR ANTAGONIST AND SORBITOL
#381INHALATION COMPOSITIONS COMPRISING CORTICOSTEROID AND SORBITOL
#382Inhalation compositions comprising glucose anhydrous
#383COMBINATION THERAPY FOR TREATMENT OF MULTIPLE SCLEROSIS
#384THERAPEUTIC AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND METHOD FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE USING THE SAME
#385Inhalation compositions comprising muscarinic receptor antagonist
#386Treatment of Glaucoma Using Laquinimod
#387Rebamipide prodrugs, preparation method and use thereof
#388NOVEL DOSAGE FORM AND FORMULATION OF ABEDITEROL
#389Methods and compositions for the inhibition of Pin1
#390Therapeutic agent for lower urinary tract disease
#391Laquinimod Combination Therapy For Treatment Of Multiple Sclerosis
#392TREATMENT OF LUPUS ARTHRITIS USING LAQUINIMOD
#393SALTS OF 5-[(1R)-2-(AMINO)-1-HYDROXYETHYL]-8-HYDROXYQUINOLIN-2(1H)-ONE
#394Heterocyclic GSK-3 allosteric modulators
#395Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor
#396Selective β-glucuronidase inhibitors as a treatment for side effects of camptothecin antineoplastic agents
#3972-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
#398Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
#399TREATMENT OF LUPUS NEPHRITIS USING LAQUINIMOD
#400TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FLUPIRTINE
#401Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
#402Positive allosteric modulators for melanocortin receptors
#403FN14 antagonists and therapeutic uses thereof
#404Tetrahydrofolates in combination with EGFR-inhibitors
#405Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate
#406Methods of Treating Adverse Intestinal Effects of Non-Steroidal Anti-Inflammatory Drugs
#4071-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors
#408Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear disorders
#409Compositions and methods for treating extracellular parasitic infections
#410Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
#4115-(2-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE FOR THE TREATMENT OF LUNG FUNCTION
#412Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
#413COMPOSITION FOR PREVENTING OR TREATING OBESITY COMPRISING REBAMIPIDE
#414COLLATERAL BLOOD CIRCULATION DEVELOPMENT PROMOTER
#415Materials and methods for modulating immune responses
#416Pharmaceutical Composition
#417Respirable agglomerates of porous carrier particles and micronized drug
#418TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS WITH LAQUINIMOD
#419Agents and methods for treating ischemic and other diseases
#420Pharmaceutical compositions
#421Method of modulating stress-activated protein kinase system
#422TREATMENT OF CROHN'S DISEASE WITH LAQUINIMOD
#423Molecules inhibiting a metabolic pathway involving the Syk protein tyrosine kinase and method for identifying said molecules
#424Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
#425Methods of using pyruvate kinase activators
#426Pharmaceutical composition
#427Anthelmintic compounds and compositions and method of using thereof
#428Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
#429LAQUINIMOD FOR REDUCING THALAMIC DAMAGE IN MULTIPLE SCLEROSIS
#430TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD
#431COMBINATION OF LAQUINIMOD AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE
#432TREATMENT OF CROHN'S DISEASE WITH LAQUINIMOD
#433DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF
#434LAQUINIMOD FOR TREATMENT OF CANNABINOID RECEPTOR TYPE 1(CB1) MEDIATED DISORDERS
#435Laquinimod for treatment of GABA mediated disorders
#436Rebamipide complexes and cocrystals
#4375-(2--1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2 (1H)-ONE AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES
#438NOVEL AZACOUMARIN DERIVATIVES HAVING MDR PUMP INHIBITING ACTIVITY
#439Compound composition for inhalation used for treating asthma
#440Stable laquinimod preparations
#441METHODS FOR INDUCING MITOCHONDRIAL BIOGENESIS
#442LAQUINIMOD FORMULATIONS WITHOUT ALKALIZING AGENT
#443Methods for modulating function of proliferating cell nuclear antigen (PCNA) and treating cancer with PCNA-targeting compounds
#444TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FAMPRIDINE
#445PHARMACEUTICAL COMPOSITION FOR TREATING A DISEASE IN THE ORAL CAVITY COMPRISING REBAMIPIDE
#446Process for preparing quinoline-3-carboxamide derivatives
#447COMPOSITION FOR LUPUS NEPHRITIS AND METHODS OF MAKING AND USING THE SAME
#448N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide
#449PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF
#450Pharmaceutical Compositions
#451TREATMENT OF OCULAR INFLAMMATORY DISEASES USING LAQUINIMOD
#452Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
#453Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases
#454USE OF HIGH DOSE LAQUINIMOD FOR TREATING MULTIPLE SCLEROSIS
#455Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use
#456TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD
#457Quinolinone derivatives
#458TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND DIMETHYL FUMARATE
#459Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists
#460N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
#461Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy
#462TREATMENT OF LUPUS ARTHRITIS USING LAQUINIMOD
#463Bicyclic heteroaryl inhibitors of PDE4
#464TRPV1 antagonists
#465ANTIMETASTATIC COMPOUNDS
#466PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF
#467Crystalline salts of quinoline compounds and methods for preparing them
#468BICYCLIC HETEROARYL INHIBITORS OF PDE4
#469Treatment of multiple sclerosis with combination of laquinimod and fingolimod
#470Use of isoquinolones for preparing drugs, novel isoquinolones and method for synthesising same
#471CRYSTALLINE MICROPARTICLES OF A BETA-AGONIST COATED WITH A FATTY ACID
#472HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS
#473Pharmaceutical Combinations
#474Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
#475Pharmaceutical composition for the prevention or treatment of osteoarthritis containing rebamipide as an active ingredient
#476OPHTHALMIC COMPOSITION
#477BICYCLIC HETEROARYL INHIBITORS OF PDE4
#478Compounds having muscarinic receptor antagonist and beta2 Adrenergic receptor agonist activity
#479TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND GLATIRAMER ACETATE
#480TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND INTERFERON-BETA
#4811-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS
#482Selective beta-glucuronidase inhibitors as a treatment for side effects of camptothecin antineoplastic agents
#483Quinolone compound and pharmaceutical composition
#484Stable laquinimod preparations
#485Treatment for Amyotrophic Lateral Sclerosis
#486Method of modulating stress-activated protein kinase system
#4875-HT1A receptor subtype agonist
#488METHOD FOR PRODUCING PULVERIZED ORGANIC COMPOUND PARTICLE
#489Stable laquinimod preparations
#490Compositions and methods for treating extracellular parasitic infections
#491Treatment for multiple sclerosis
#492Pharmaceutical composition for preventing or treating rheumatoid arthritis, containing rebamipide
#493Method of treating cognitive impairments and schizophrenias
#494USE OF LAQUINIMOD FOR REDUCING FATIGUE, IMPROVING FUNCTIONAL STATUS, AND IMPROVING QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS
#495Method of treating cancer using a survivin inhibitor
#496Mixtures or Organic Compounds for the Treatment of Airway Diseases
#497Prevention and treatment of sarcopenia
#498Method of treating neurodegenerative diseases
#499Method of treating down's syndrome
#5005-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES
#5015-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2 (1H)-ONE FOR THE TREATMENT OF LUNG FUNCTION
#502BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME
#503BICYCLIC MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME
#5045-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF
#505Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
#506Method of treating panic disorder
#507TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR
#508Method of treating autism
#509Ophthalmic composition
#510STABLE LAQUINIMOD PREPARATIONS
#511Agents and methods for treating ischemic and other diseases
#512HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA
#513Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate
#514Treatment of lupus nephritis using laquinimod
#515TREATMENT OF LUPUS ARTHRITIS USING LAQUINIMOD
#516Solid state forms of laquinimod and its sodium salt
#517TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED BETA 2-AGONIST OR COMBINED NEBULIZED BETA 2-AGONIST AND ANTICHOLINERGIC ADMINISTRATION
#518PHARMACEUTICAL COMPOSITION COMPRISING REBAMIPIDE
#519Crystals of laquinimod sodium, and process for the manufacture thereof
#520NRF2 SCREENING ASSAYS AND RELATED METHODS AND COMPOSITIONS
#521Crystals of laquinimod sodium, and process for the manufacture thereof
#522MOLECULES INHIBITING A METABOLIC PATHWAY INVOLVING THE SYK PROTEIN TYROSINE KINASE AND METHOD FOR IDENTIFYING SAID MOLECULES
#523Process for preparing quinoline-3-carboxamide derivatives
#524Eye-drop preparation and use thereof
#525PARTICLES COMPRISING A SALT OF 8-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AMINO]ETHYL]-2(1H)-QUINOLINONE HAVING IMPROVED ADHESION PROPERTIES FOR POWDER FORMULATIONS FOR INHALATION
#526Formoterol superfine formulation
#527TREATMENT OF MITOCHONDRIAL DISORDERS USING A FARNESYL TRANSFERASE INHIBITOR
#528Multitarget Compounds Active at a PPAR and Cannabinoid Receptor
#529Treatment of BDNF-related disorders using laquinimod
#530COMPOUNDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN
#531Treatment of Crohn's disease with laquinimod
#532Combination of a carbostyril and carnitine
#533Treatment method for anemia
#534Treatment of multiple sclerosis with laquinimod
#535Isoquinolone compounds as subtype-selective agonists for melatonin receptors MTand MT
#536METHODS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS RELATED TO GASTRIC ACID SECRETION
#537Treatment of cachexia
#538Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
#539METHOD OF TREATING COGNITIVE IMPAIRMENTS AND SCHIZOPHRENIAS
#540IBUDILAST AND IMMUNOMODULATORS COMBINATION
#541Use of beta-adrenoceptor antagonists for the manufacture of a medicament of the treatment of disorders of the outer retina
#542METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM
#543New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders
#5441-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors
#545PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-beta PROTEIN ACCUMULATION
#546Process of making crystalline type II aripiprazole
#547Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
#548DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL)PHENOL AS AGONISTS OF THE BETA2 ADRENERGIC RECEPTOR
#549TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR
#550Quinolone compound and pharmaceutical composition
#551Drug combination and its use in the treatment of muscle loss
#552METHODS AND COMPOUNDS FOR MODULATING INFLAMMATORY PROCESSES
#553Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
#554MEDICINAL COMPOSITIONS QUICKLY DISINTEGRATING IN THE ORAL CAVITY AND PROCESS FOR PRODUCING THE SAME
#555METHODS AND COMPOSITIONS FOR PRESERVING THE VIABILITY OF PHOTORECEPTOR CELLS
#556MIXTURES OR ORGANIC COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES
#557Pharmaceutical Combinations
#558Micronized particles of low-dosage strength active agents for powder formulations for inhalation
#559PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS
#560Aqueous pharmaceutical suspensions containing rebamipide and manufacturing process thereof
#561Bicyclic heteroaryl inhibitors of PDE4
#562Method for producing pulverized organic compound particle
#5635-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1-arylquinolin-2-ones, a Process for their Production and their Use as Anti-inflammatory Agents
#564PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CELLULITE
#565BICYCLIC HETEROARYL INHIBITORS OF PDE4
#566Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
#567PRESSURISED METERED DOSE INHALERS CONTAINING SOLUTIONS OF BETA-2 AGONISTS
#568Novel Combinations of DNAK Inhibitors With Known Antibacterial Agents
#569Organic compounds
#570Crystalline salts of quinoline compounds and methods for preparing them
#571NOVEL TRIGLYCERIDE REDUCING AGENT
#572Novel salt form of a Beta2-adrenergic agonist quinolin-2-one derivative
#5735-HT1A RECEPTOR SUBTYPE AGONIST
#574Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects
#575Stable laquinimod preparations
#576MEDICAMENTS FOR INHALATION COMPRISING AN ANTICHOLINERGIC AND A BETAMIMETIC
#577PHARMACEUTICAL SOLUTION FORMULATIONS FOR PRESSURISED METERED DOSE INHALERS
#578Treatments for Viral Infections
#579Treatment of Microbial Infections
#580Methods and compositions for the treatment of conditions related to gastric acid secretion
#581Organic compounds
#582Method of treating neurodegenerative diseases
#5835-HT1A RECEPTOR SUBTYPE AGONIST
#584Antipruritics
#585Pharmaceutical Compositions for the Treatment of Inflammatory and Obstructive Airways Diseases
#586Treatment of Asthma and Copd Using Triple-Combination Therapy
#587Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists
#588Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
#589Organic compounds
#590Compositions For Progeny Gender Control
#591Method of treating Attention Deficit Hyper-Activity Disorder
#592Compositions and methods for treatment of viral diseases
#593QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS
#594USE OF BETA-ADRENOCEPTOR ANTAGONISTS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DISORDERS OF THE OUTER RETINA
#595Treatment of Inflammatory Disorders and Pain
#596Combination therapy of erdosteine and beta-2 agonists for treating respiratory pathologies characterized by non reversible or partially reversible airway obstruction
#597Bicyclic heteroaryl inhibitors of PDE4
#598Bicyclic heteroaryl inhibitors of PDE4
#599Stable laquinimod preparations
#600Aqueous ophthalmic suspension of crystalline rebamipide